Emerging concepts in heart failure management and treatment: focus on vericiguat.
VICTORIA trial
guanylate cyclase stimulators
heart failure
vericiguat
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
05
2022
accepted:
26
07
2022
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is dysregulated in patients with heart failure (HF) resulting in myocardial and vascular dysfunction that contributes to its progression. Vericiguat is a novel direct sGC stimulator that targets in at least two ways the NO-sGC-cGMP pathway with the subsequent restoration of cGMP activity. The VICTORIA trial assessed the effects of vericiguat (
Identifiants
pubmed: 36660012
doi: 10.7573/dic.2022-5-5
pii: dic-2022-5-5
pmc: PMC9828868
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
Copyright © 2023 Kaplinsky E, Perrone S, Barbagelata A.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/08/dic.2022-5-5-COI.pdf
Références
Eur J Heart Fail. 2021 Aug;23(8):1300-1312
pubmed: 34191395
J Clin Med. 2022 Jan 11;11(2):
pubmed: 35054042
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Congest Heart Fail. 2002 May-Jun;8(3):142-7, 155
pubmed: 12045382
Eur J Heart Fail. 2022 May;24(5):782-790
pubmed: 35239245
Clin Pharmacokinet. 2020 Nov;59(11):1407-1418
pubmed: 32458378
Nat Rev Cardiol. 2015 Apr;12(4):220-9
pubmed: 25666406
Circulation. 2021 Nov 2;144(18):1489-1499
pubmed: 34432985
JACC Heart Fail. 2014 Jun;2(3):269-77
pubmed: 24952694
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
Br J Pharmacol. 2007 Nov;152(6):855-69
pubmed: 17700722
Basic Clin Pharmacol Toxicol. 2020 Aug;127(2):67-80
pubmed: 31495057
Nat Rev Drug Discov. 2006 Sep;5(9):755-68
pubmed: 16955067
Eur J Heart Fail. 2021 Aug;23(8):1313-1321
pubmed: 33999486
JACC Heart Fail. 2022 Feb;10(2):73-84
pubmed: 34895860
Eur J Heart Fail. 2017 Sep;19(9):1095-1104
pubmed: 28470962
Cardiovasc Drugs Ther. 2021 Oct;35(5):1067-1076
pubmed: 33074526
Eur Heart J. 2017 Apr 14;38(15):1119-1127
pubmed: 28369340
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
N Engl J Med. 2020 May 14;382(20):1883-1893
pubmed: 32222134
JAMA. 2020 Oct 20;324(15):1512-1521
pubmed: 33079152
JACC Heart Fail. 2020 Nov;8(11):931-939
pubmed: 33039447
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
JAMA. 2015 Dec 1;314(21):2251-62
pubmed: 26547357
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
J Card Fail. 2022 May;28(5):e1-e167
pubmed: 35378257
Physiol Rev. 2007 Jan;87(1):315-424
pubmed: 17237348
Circulation. 2003 Nov 4;108(18):2172-83
pubmed: 14597579
Circ Res. 2017 Mar 31;120(7):1174-1182
pubmed: 28360348